Skip to main content Skip to section navigation Skip to footer
Avalo Therapeutics, Inc. Corporate Home
  • About
    • Overview
    • Leadership
    • Board of directors
    • Register for updates
    • Contact
  • Science
    • Overview
    • IL-1β in HS
    • IL-1β in CPPD
  • Pipeline
    • Overview
    • AVTX-009 for HS
    • AVTX-009 for CPPD
  • Patients
    • Our commitment
    • Clinical trials
    • Resources
    • Access to investigational therapies
  • Investors
    • Overview
    • News, events & presentations
    • Analyst coverage
    • Stock data
    • SEC filings
    • Corporate governance
    • IR resources
  • Careers
    • Overview
    • Values
    • Benefits
    • Job openings

Press Releases

News, events & presentations

News, events & presentations

  • Press Releases
  • Events
  • Presentations
  • Email alerts
May 26, 2020 7:00 am EDT
Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
May 7, 2020 6:30 am EDT
Cerecor Reports Q1 2020 Results and Update
Apr 24, 2020 1:45 pm EDT
Cerecor Announces Changes to Board of Directors
Mar 26, 2020 6:30 am EDT
Cerecor Announces Exploration of the Role of an Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to Acute Respiratory Distress Syndrome
Mar 11, 2020 6:30 am EDT
Cerecor Reports 2019 Results
Mar 6, 2020 9:00 am EST
Cerecor Announces Appointment of H. Jeffery Wilkins MD as Chief Development Officer
Feb 3, 2020 4:15 pm EST
Cerecor and Aevi Genomic Medicine Complete Merger
Dec 5, 2019 8:45 am EST
Cerecor to Acquire Aevi Genomic Medicine
Nov 14, 2019 6:30 am EST
Cerecor Reports Third Quarter 2019 Results
Nov 11, 2019 6:30 am EST
Cerecor Announces Clinical Updates on CERC-301 and CERC-802
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • …
  • Page 21
  • Next Pagearrow_forward
  • Contact IR
  • RSS
  • Email Alerts
  • Accessibility
    accessibility
610.254.4205
in
1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087
Avalo
PRIVACY POLICY DISCLAIMER
©2026 Avalo Therapeutics, Inc.